Inhibition of cathecol-O-methyltransferase (COMT) in the brain does not affect the action of dopamine and levodopa: An in vitro electrophysiological evidence from rat mesencephalic dopamine neurons

Journal of Neural Transmission

Volumn 106, Issue 11-12, 1999, Pages 1135-1140

  Mercuri, N B ^a,b   Federici, M ^a   Bernardi, G ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Intracellular recordings; Parkinson's disease; Substantia nigra; Ventral tegmental area

Indexed keywords

CATECHOL METHYLTRANSFERASE; DOPAMINE; LEVODOPA; TOLCAPONE; 3 AMINOPROPYL(DIETHOXYMETHYL)PHOSPHINIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; AMINO ACID RECEPTOR AFFECTING AGENT; BENZOPHENONE DERIVATIVE; DOPAMINE RECEPTOR BLOCKING AGENT; ENZYME INHIBITOR; NITROPHENOL; ORGANOPHOSPHORUS COMPOUND; PICROTOXIN; STRYCHNINE; SULPIRIDE;

ANIMAL CELL; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; ENZYME INHIBITION; HYPERPOLARIZATION; INTRACELLULAR RECORDING; MALE; MESENCEPHALON; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM; ANIMAL; CELL CULTURE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; ELECTROPHYSIOLOGY; ENZYMOLOGY; NERVE CELL; PHYSIOLOGY; SYNAPTIC TRANSMISSION; WISTAR RAT;

ANIMALS; BENZOPHENONES; CATECHOL O-METHYLTRANSFERASE; CELLS, CULTURED; DOPAMINE; DOPAMINE ANTAGONISTS; ELECTROPHYSIOLOGY; ENZYME INHIBITORS; GABA ANTAGONISTS; GLYCINE AGENTS; LEVODOPA; MALE; NEURONS; NITROPHENOLS; ORGANOPHOSPHORUS COMPOUNDS; PARKINSON DISEASE; PICROTOXIN; RATS; RATS, WISTAR; STRYCHNINE; SUBSTANTIA NIGRA; SULPIRIDE; SYNAPTIC TRANSMISSION; VENTRAL TEGMENTAL AREA;

EID: 0033233154     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020050229     Document Type: Article

References (22)

1. Adler CH, Singer C, O'Brien C, Hauser RA, Lew MF, Marek KL, Dorflinger E, Pedder S, Deptula D, Kisook Y (1998) Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Arch Neurol 55: 1089-1095
2. Brannan T, Martinez-Tica J, Yahr MD (1992) Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine an in vivo study in rats. Neurology 42: 683-685
3. Djaldetti R, Melamed E (1998) Management of response fluctuations: practical guidelines. Neurology 51: S36-40
4. Grace AA, Onn SP (1989) Morphology and electrophysiological properties of immuno-cytochemically identified rat dopamine neurons recorded in vitro. J Neurosci 9: 3463-3481
5. Guldberg HC, Marsden CA (1975) Catechol-O-methyltransferase: pharmacological aspects and physiological role. Pharmacol Rev 27: 135-206
6. Johnson SW, North RA (1992) Two types of neurons in the rat ventral tegmental area and their synaptic inputs. J Physiol 450: 455-468
7. Kaakkola S, Wurtman RJ (1993) Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum. J Neurochem 60: 137-144
8. Kurth MC, Adler CH (1998) COMT inhibition: a new treatment strategy for Parkinson's disease. Neurology 50: S5 3-14
9. Lacey MG, Mercuri NB, North RA (1987) Dopamine acts on D2 receptors to increase potassium conductances in neurones of the rat substantia nigra zona compacta. J Physiol 392: 397-416
10. Lacey MG, Mercuri NB, North RA (1989) Two cell types in rat substantia nigra zona compacta distinguished by membrane properties and the action of dopamine and opioids. J Neurosci 9: 1233-1241
11. Lacey MG, Mercuri NB, North RA (1990) Actions of cocaine on rat dopaminergic neurones in vitro. Br J Pharmacol 98: 731-735
12. Maj J, Rooz Z, Skuza G, Sowiska IT, Superata J (1990) Behavioural and neurochemical effects of RO 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease. J Neural Transm [PD-Sect] 2: 101-112
13. Mannisto PT (1994) Clinical potential of catechol-O-methyltransferase (COMT) inhibitors as adjuvants in Parkinson's disease. CNS Drugs 1: 172-179
14. Mercuri NB, Calabresi P, Bernardi G (1990) Responses of rat substantia nigra compacta neurones to L-DOPA. Br J Pharmacol 100: 257-260
15. h in rat midbrain dopaminergic neurons. Eur J Neurosci 7: 462-469
16. Mercuri NB, Bonci A, Bernardi G (1997a) Electrophysiological pharmacology of the autoreceptor-mediated responses of dopaminergic cells to antiparkinsonian drugs. Trends Pharmacol Sci 18: 232-235
17. Mercuri NB, Scarponi M, Bonci A, Siniscalchi A, Bernardi G (1997b) Monoamine oxidase inhibition causes a long-term prolongation of the dopamine-induced responses in rat midbrain dopaminergic cells. J Neurosci 17: 2267-2272
18. Mercuri NB, Scarponi M, Federici M, Bonci A, Siniscalchi A, Bernardi G (1998) Modification of levodopa responses by deprenyl (selegiline): an electrophysiologycal and behavioural study in the rat relevant to Parkinson's disease. Ann Neurol 43: 613-617
19. Napolitano A, Zurker G, Da Prada M (1995) Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats. Eur J Pharmacol 273: 215-221
20. Schoepp DD, Azzaro AJ (1982) The role of type A and type B monoamine oxidase in the metabolism of released [3H]dopamine from rat striatal slices. Biochem Pharmacol 31: 2961-2968
21. Weiner N, Molinoff PB (1989) Storage and release of catecholamines. In: Siegel G, Agranoff B, Albers RW, Molinoff P (eds) Basic neurochemistry: molecular, cellular, and medical aspects. Raven Press, New York, pp 236-239
22. Yang HY, Neff NH (1974) The monoamine oxidase of brain: selective inhibition with drugs and the consequence for the metabolism of biogenic amine. J Pharmacol Exp Ther 189: 733-740